Stanley Plokin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9551284/publications.pdf

Version: 2024-02-01

96	8,264	66343	49909
papers	citations	42 h-index	87 g-index

103	103	103	10430
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Towards a population-based threshold of protection for COVID-19 vaccines. Vaccine, 2022, 40, 306-315.	3.8	107
2	The scourge of vaccine falsification. Vaccine, 2022, 40, 2126-2128.	3.8	4
3	Titerphilia - The Irresistible Urge to Measure Postimmunization Antibody Values. Pediatric Infectious Disease Journal, 2022, 41, 490-491.	2.0	1
4	Obituary of Robert Daum - Expert in Staphylococcal Disease. Human Vaccines and Immunotherapeutics, 2022, 18, 1.	3.3	0
5	Correlates of protection against <scp>SARS</scp>â€<scp>CoV</scp>â€2 infection and COVIDâ€19 disease. Immunological Reviews, 2022, 310, 6-26.	6.0	138
6	Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-monitored Challenge Model of Coronavirus Disease 2019 (COVID-19) in Healthy Volunteers. Clinical Infectious Diseases, 2021, 72, 2035-2041.	5.8	15
7	Accelerate Coronavirus Disease 2019 (COVID-19) Vaccine Rollout by Delaying the Second Dose of mRNA Vaccines. Clinical Infectious Diseases, 2021, 73, 1320-1321.	5.8	10
8	Considering Mandatory Vaccination of Children for COVID-19. Pediatrics, 2021, 147, .	2.1	38
9	COVID vaccine efficacy against the B.1.351 (â€œSouth Africanâ€) variantâ€”The urgent need to lay the groundwork for possible future challenge studies. Human Vaccines and Immunotherapeutics, 2021, , 1-2.	3.3	5
10	Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine, 2021, 39, 4423-4428.	3.8	766
11	Rubella Eradication: Not Yet Accomplished, but Entirely Feasible. Journal of Infectious Diseases, 2021, 224, S360-S366.	4.0	22
12	What have we learned from the COVID-19 plague?. Science Translational Medicine, 2021, 13, eabl9098.	12.4	2
13	The influence of interval between doses on response to vaccines. Vaccine, 2021, 39, 7123-7127.	3.8	9
14	Dengue Vaccine, A Double-Edged Sword. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 107-109.	1.3	4
15	Protective Immunity and New Vaccines for Lyme Disease. Clinical Infectious Diseases, 2020, 70, 1768-1773.	5.8	50
16	Is There a Correlate of Protection for Measles Vaccine?. Journal of Infectious Diseases, 2020, 221, 1571-1572.	4.0	8
17	Updates on immunologic correlates of vaccine-induced protection. Vaccine, 2020, 38, 2250-2257.	3.8	119
18	Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 517-518.	1.3	0

#	Article	IF	Citations
19	Tetanus and Diphtheria Boosters. Clinical Infectious Diseases, 2020, 71, 3266-3267.	5.8	1
20	Dengue vaccines: the road to failure or to success?. Human Vaccines and Immunotherapeutics, 2020, 16, 2677-2679.	3.3	1
21	Impact of Vaccines; Health, Economic and Social Perspectives. Frontiers in Microbiology, 2020, 11, 1526.	3.5	282
22	Preventing Infection by Human Cytomegalovirus. Journal of Infectious Diseases, 2020, 221, S123-S127.	4.0	16
23	The Status of Vaccine Development Against the Human Cytomegalovirus. Journal of Infectious Diseases, 2020, 221, S113-S122.	4.0	73
24	The New Coronavirus, the Current King of China. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 1-2.	1.3	8
25	The science of vaccine safety: Summary of meeting at Wellcome Trust. Vaccine, 2020, 38, 1869-1880.	3.8	19
26	Extraordinary diseases require extraordinary solutions. Vaccine, 2020, 38, 3987-3988.	3.8	62
27	Measles: Breakouts and Breakthroughs. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 289-290.	1.3	10
28	Infectious vaccine-derived rubella viruses emerge, persist, and evolve in cutaneous granulomas of children with primary immunodeficiencies. PLoS Pathogens, 2019, 15, e1008080.	4.7	58
29	How to Prepare for Expert Testimony on the Safety of Vaccination. Pediatrics, 2019, 143, e20183578.	2.1	1
30	Chikungunya Virus: A Back-Breaking Problem. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 95-96.	1.3	1
31	Influenza in Latin America: A report from the Global Influenza Initiative (GII). Vaccine, 2019, 37, 2670-2678.	3.8	17
32	The changing epidemiology of mumps in a high vaccination era. Lancet Infectious Diseases, The, 2019, 19, 118-119.	9.1	20
33	The National Vaccine Injury Compensation Program. JAMA - Journal of the American Medical Association, 2019, 321, 343.	7.4	19
34	Vaccination against the human cytomegalovirus. Vaccine, 2019, 37, 7437-7442.	3.8	92
35	Advancing Our Understanding of Protective Maternal Immunity as a Guide for Development of Vaccines To Reduce Congenital Cytomegalovirus Infections. Journal of Virology, 2018, 92, .	3.4	60
36	Vaccine mandates in France will save lives. Science, 2018, 359, 283-284.	12.6	2

#	Article	IF	Citations
37	Vaccines We Need But Don't Have. Viral Immunology, 2018, 31, 114-116.	1.3	6
38	Ten yearly yellow fever booster vaccinations may still be justified. Journal of Travel Medicine, 2018, 25, .	3.0	18
39	Important New Resource for Clinicians Giving Expert Witness Testimony on Vaccines. Pediatric Infectious Disease Journal, 2018, 37, e353-e353.	2.0	1
40	Portait of an ISV fellow. Human Vaccines and Immunotherapeutics, 2018, 14, 1836-1839.	3.3	1
41	Recommendations to control pertussis prioritized relative to economies: A Global Pertussis Initiative update. Vaccine, 2018, 36, 7270-7275.	3.8	28
42	Lemons and Lyme. Journal of the Pediatric Infectious Diseases Society, 2018, 7, 267-269.	1.3	1
43	Reply to Gantt et al., â€œHigher Expectations for a Vaccine To Prevent Congenital Cytomegalovirus Infectionâ€• Journal of Virology, 2018, 92, .	3.4	4
44	Mumps: A Pain in the Neck. Journal of the Pediatric Infectious Diseases Society, 2018, 7, 91-92.	1.3	15
45	The Influenza Vaccine Mess. Journal of the Pediatric Infectious Diseases Society, 2018, 7, 178-180.	1.3	2
46	Seroconversion for Cytomegalovirus Infection During Pregnancy and Fetal Infection in a Highly Seropositive Population: â€œThe BraCHS Study,â€•by Mussi-Pinhata et al. Journal of Infectious Diseases, 2018, 218, 1188-1190.	4.0	6
47	New Vaccines against Epidemic Infectious Diseases. New England Journal of Medicine, 2017, 376, 610-613.	27.0	70
48	Complex immune correlates of protection in <scp>HIV</scp>â€1 vaccine efficacy trials. Immunological Reviews, 2017, 275, 245-261.	6.0	95
49	Human capital gaps in vaccine development: an issue for global vaccine development and global health. Annals of the New York Academy of Sciences, 2017, 1395, 3-11.	3.8	10
50	Correlates of protection for enteric vaccines. Vaccine, 2017, 35, 3355-3363.	3.8	54
51	Vaccines for epidemic infections and the role of CEPI. Human Vaccines and Immunotherapeutics, 2017, 13, 2755-2762.	3.3	44
52	What Is Wrong with Pertussis Vaccine Immunity?. Cold Spring Harbor Perspectives in Biology, 2017, 9, a029454.	5.5	82
53	Whither vaccines?. Journal of Infection, 2017, 74, S2-S9.	3.3	19
54	Third Dose of MMR Vaccine for Mumps Control. New England Journal of Medicine, 2017, 377, 2402-2403.	27.0	12

#	Article	IF	Citations
55	Rubella persistence in epidermal keratinocytes and granuloma M2 macrophages in patients with primary immunodeficiencies. Journal of Allergy and Clinical Immunology, 2016, 138, 1436-1439.e11.	2.9	73
56	A Phase 1 Study of 4 Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimera Vaccines in Cytomegalovirusâ€“Seronegative Men. Journal of Infectious Diseases, 2016, 214, 1341-1348.	4.0	44
57	White Paper on studying the safety of the childhood immunization schedule in the Vaccine Safety Datalink. Vaccine, 2016, 34, A1-A29.	3.8	35
58	The history of vaccination against cytomegalovirus. Medical Microbiology and Immunology, 2015, 204, 247-254.	4.8	62
59	Strategies to Decrease Pertussis Transmission to Infants. Pediatrics, 2015, 135, e1475-e1482.	2.1	120
60	Global incidence of serogroup B invasive meningococcal disease: a systematic review. Lancet Infectious Diseases, The, 2015, 15, 1334-1346.	9.1	71
61	Establishing a Global Vaccine-Development Fund. New England Journal of Medicine, 2015, 373, 297-300.	27.0	79
62	Pertussis: pertussis control strategies and the options for improving current vaccines. Expert Review of Vaccines, 2014, 13, 1071-1072.	4.4	8
63	Enveloped Virus-Like Particle Expression of Human Cytomegalovirus Glycoprotein B Antigen Induces Antibodies with Potent and Broad Neutralizing Activity. Vaccine Journal, 2014, 21, 174-180.	3.1	74
64	Problems in Vaccine Development. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2014, 33, 166-167.	1.6	3
65	History of vaccination. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 12283-12287.	7.1	440
66	The Pertussis Problem. Clinical Infectious Diseases, 2014, 58, 830-833.	5.8	93
67	Priorities for CMV vaccine development. Vaccine, 2013, 32, 4-10.	3.8	122
68	The History of Vaccines.org publishes a book. Vaccine, 2013, 31, 4697.	3.8	0
69	A hepatitis B vaccine with a novel adjuvant. Vaccine, 2013, 31, 5297-5299.	3.8	5
70	Complex Correlates of Protection After Vaccination. Clinical Infectious Diseases, 2013, 56, 1458-1465.	5.8	225
71	Commentary: In Memoriam: Hilary Koprowski, 1916â€“2013. Journal of Virology, 2013, 87, 8270-8271.	3.4	5
72	Commentary. Pediatric Infectious Disease Journal, 2013, 32, 381-382.	2.0	24

#	Article	IF	Citations
73	Nomenclature for Immune Correlates of Protection After Vaccination. Clinical Infectious Diseases, 2012, 54, 1615-1617.	5.8	297
74	In Memoriam. Human Vaccines and Immunotherapeutics, 2012, 8, 1321-1322.	3.3	0
75	The development of vaccines: how the past led to the future. Nature Reviews Microbiology, 2011, 9, 889-893.	28.6	222
76	Correcting a Public Health Fiasco: The Need for a New Vaccine against Lyme Disease. Clinical Infectious Diseases, 2011, 52, s271-s275.	5.8	50
77	Correlates of Protection Induced by Vaccination. Vaccine Journal, 2010, 17, 1055-1065.	3.1	1,365
78	The enemy is sometimes us. Hum Vaccin, 2010, 6, 282-282.	2.4	0
79	The RV144 Thai HIV vaccine trial. Hum Vaccin, 2010, 6, 157-163.	2.4	11
80	A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes. Hum Vaccin, 2010, 6, 841-848.	2.4	30
81	Vaccines: the Fourth Century. Vaccine Journal, 2009, 16, 1709-1719.	3.1	205
82	Vaccines: Correlates of Vaccineâ€Induced Immunity. Clinical Infectious Diseases, 2008, 47, 401-409.	5.8	693
83	Prevention of pertussis: Recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine, 2007, 25, 2634-2642.	3.8	145
84	The History of Rubella and Rubella Vaccination Leading to Elimination. Clinical Infectious Diseases, 2006, 43, S164-S168.	5.8	97
85	New Rotavirus Vaccines. Pediatric Infectious Disease Journal, 2006, 25, 575-576.	2.0	12
86	Vaccines, Vaccination, and Vaccinology. Journal of Infectious Diseases, 2003, 187, 1349-1359.	4.0	76
87	Vaccines in the 21st Century. Hybridoma, 2002, 21, 135-145.	0.4	2
88	Immunologic correlates of protection induced by vaccination. Pediatric Infectious Disease Journal, 2001, 20, 63-75.	2.0	215
89	A Canarypox Vectorâ€“Expressing Cytomegalovirus (CMV) Phosphoprotein 65 Induces Longâ€Lasting Cytotoxic T Cell Responses in Human CMVâ€Seronegative Subjects. Journal of Infectious Diseases, 2001, 183, 1171-1179.	4.0	138
90	Responding to The River. Science, 1999, 286, 2449d-2449.	12.6	23

#	Article	IF	Citations
91	Delayed type hypersensitivity to human cytomegalovirus. Journal of Medical Virology, 1993, 39, 109-117.	5.0	6
92	A Controlled Trial Comparing Vidarabine with Acyclovir in Neonatal Herpes Simplex Virus Infection. New England Journal of Medicine, 1991, 324, 444-449.	27.0	375
93	Half-Dose Immunization for Diphtheria, Tetanus, Pertussis. Pediatrics, 1990, 86, 145-145.	2.1	2
94	Protective Effects of Towne Cytomegalovirus Vaccine Against Low-Passage Cytomegalovirus Administered as a Challenge. Journal of Infectious Diseases, 1989, 159, 860-865.	4.0	153
95	The virus susceptibility of skin-derived fibroblasts from families with insulin-dependent diabetes mellitus. Journal of Medical Virology, 1982, 9, 281-292.	5.0	1
96	Enhancement of Vaginal Infection in Mice by Herpes Simplex Virus Type II with Progesterone. Experimental Biology and Medicine, 1978, 158, 131-134.	2.4	58